Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls ...

A University of Colorado study links air pollution to increased ocular health issues, finding patient visits for irritation and allergies more than double during high particulate matter levels, ...

The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ...

Retinal specialists conclude their discussion with key highlights from each patient case of retinal vascular disease and ...

SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug ...

EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates ...

The funding will primarily support advancement of Elate Ocular through its registration-enabling phase 3 clinical trials for ...

About 33% of ocular tuberculosis patients may relapse within 2 years of achieving clinical inactivity, with a poor initial ...

Ahead of this year's Floretina meeting and International Congress on OCT Angiography, En Face OCT and Advances in OCT (ICOOR), David Hutton of Ophthalmology Times spoke with Charles Wykoff, MD, PhD.